# BP1001-A in Patients With Advanced or Recurrent Solid Tumors

> **NCT04196257** · PHASE1 · RECRUITING · sponsor: **Bio-Path Holdings, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Endometrial Cancer
- Peritoneal Cancer
- Solid Tumor

## Interventions

- **DRUG:** BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
- **DRUG:** BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

## Key facts

- **NCT ID:** NCT04196257
- **Lead sponsor:** Bio-Path Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-19
- **Primary completion:** 2027-07
- **Final completion:** 2027-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196257, "BP1001-A in Patients With Advanced or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04196257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*